NCT06361095 Confirmatory Efficacy Trial of Attention Bias Modification for Depression
| NCT ID | NCT06361095 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Texas at Austin |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 600 participants in total. It began in 2024-05-01 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are: * Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM * Aim 1: establish that gamified ABM is at least as effective as traditional ABM. * Aim 2: identify moderators of ABM efficacy and mechanisms responsible for its efficacy. * Aim 3: Identify the durability of ABM on depression symptoms during short-term follow-up Participants will complete self-report questionnaires, complete eye-tracking tasks, and be clinically assessed through interviews by clinician researchers. If there is a comparison group: Researchers will compare sham, traditional, and gamified treatment groups to see if they moderate symptoms of depression.
Eligibility Criteria
Inclusion Criteria: * Provided informed consent * Fluent in English * Scored 13 or greater on the QIDS-SR at the baseline assessment * Between the ages of 18 to 70 * Have had no changes in medication and dosage in the past 12 weeks (if currently on antidepressant medication) Exclusion Criteria: * Reported suicidal behavior or significant suicidal ideation within the past six months using the Columbia-Suicide Severity Rating Scale (C-SSRS) * Met criteria for current or past bipolar or psychotic disorders * Current (i.e., within the past 12 months) substance use disorders of moderate or greater severity on the Mini International Neuropsychiatric Interview (MINI) * Currently taking opioid analgesics or systemic corticosteroid use as these medications * Currently receiving psychotherapy
Contact & Investigator
Christopher G Beevers, PhD
PRINCIPAL INVESTIGATOR
UT Austin
Frequently Asked Questions
Who can join the NCT06361095 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06361095 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06361095 currently recruiting?
Yes, NCT06361095 is actively recruiting participants. Contact the research team at beevers@utexas.edu for enrollment information.
Where is the NCT06361095 trial being conducted?
This trial is being conducted at Austin, United States.
Who is sponsoring the NCT06361095 clinical trial?
NCT06361095 is sponsored by University of Texas at Austin. The principal investigator is Christopher G Beevers, PhD at UT Austin. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.